Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of a woman with ophiasis-pattern alopecia areata who experienced significant hair regrowth and maintained it for 6 months after treatment with dupilumab, though she eventually relapsed.

This study used R-language data mining to analyze patents of topical Chinese medicine for hair loss, identifying key medication patterns and ingredients in traditional formulations.

This study found that androgenetic alopecia was the most common cause of hair loss among patients at Sohag University Hospital's hair clinic.

This study found that the most common cause of diffuse hair loss in Jordanian females was telogen effluvium, often triggered by nutritional deficiencies and various forms of stress.

In this study, chronic telogen effluvium was identified as the most common cause of alopecia in patients with systemic lupus erythematosus, with trichoscopy proving effective in diagnosing different alopecia patterns.

This case report describes a 45-year-old woman with diffuse nonscarring alopecia characterized by hair thinning, increased catagen/telogen follicles, and mild inflammatory infiltrate, highlighting the diagnostic findings via scalp dermoscopy and biopsy.

In this study, intradermal injections of extracellular vesicles over six months were reported to be safe and effective in improving hair growth among patients with pattern hair loss, with favorable response linked to specific patient factors and treatment volumes.

FPHL affects hair density and diameter, causing visible hair loss in older women.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This study found that the prevalence of androgenetic alopecia increases with age among both men and women in Maryborough, Australia, with 57% of women and 73.5% of men aged 80 and over affected.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.

This study found that as hair loss severity increased in women with female pattern hair loss, the number of vellus follicles also rose, indicating miniaturization of terminal hair follicles.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.

This review discusses female pattern hair loss, emphasizing its complex causes and the limited treatment options available, and reports no new clinical results.

This retrospective study found that adipose-derived stem cell-conditioned media increased hair density and thickness in women with female pattern hair loss over 12 weeks, with no severe adverse effects reported.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

In this study, genetic variation in the CYP19A1 gene, particularly the common rs4646 C allele, was associated with an increased risk of female pattern hair loss, especially in women under 40.

This study concluded that iron deficiency is common among women but not more prevalent in those with female pattern hair loss or chronic telogen effluvium compared to control subjects without hair loss.

This article discusses treatments for female pattern hair loss, highlighting that oral antiandrogens and topical minoxidil can effectively arrest progression and reverse miniaturization in many patients with mild-to-moderate cases, but it reports no new clinical results.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

Genetics and hormones cause hair loss; finasteride treats it safely.

This review discusses clinical features, differential diagnosis, and treatments for female pattern hair loss, emphasizing the use of 2% topical Minoxidil and exploring alternative off-label therapies.

This study observed that autologous PRP and PDRN injections improved hair thickness and density in women with pattern hair loss, with combined therapy showing greater improvement in thickness than PDRN alone.

This case report describes a patient with complete androgen insensitivity syndrome experiencing female pattern hair loss, suggesting that factors beyond direct androgen action may contribute to this condition in women.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.